| Factor Information | |
|---|---|
| Data ID | 3921 |
| Factor | Immunocompromised |
| Description | N/A |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To access the risk for IE between the different immune system in CHD patients |
| p Value | 0.001 |
| OR | 5.43 |
| Conclusion | In univariate Cox regression analysis, only immunocompromised status as defined in this study (underlying syndrome predisposing to infections, chronic immunosuppressive therapy, neutropenia) was associated with the development of IE. |
| Risk Factor | risk factor |
| CHD Type | |
|---|---|
| ID | 730 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | TA/TOF/PA, IVS/D-TGA/PS/D-TGA, DORV |
| Reference | |
|---|---|
| PMID | 31471941 |
| Year | 2019 |
| Title | Risk factors for infective endocarditis following transcatheter pulmonary valve replacement in patients with congenital heart disease |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | patients | |
| Region | California, USA | |
| Method | observational study | |
| Race | American | |
| Disease History | 13 patients were diagnosed with 22q11.2 deletions. | |
| Treatment History | Antibiotics | |
| Group | IE positive patients(Treatment) | IE negative patients(Control) |
| Number | 13 | 222 |
| Age | 2.6 years (range 0.0–8.0 years) | 2.6 years (range 0.0–8.0 years) |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 6 (46%) | 22 (10%) |
